Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN: Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

The clinical trial will be a study combining Novo Nordisk's semaglutide drug and Gilead's cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis , Novo Nordisk, best known for its diabetes drugs, said on Friday."NASH is a complex disease that often affects people with diabetes and metabolic syndrome. Currently, patients living with NASH have limited treatment options," said Gilead's chief scientific officer John McHutchison in a statement.

In February, Gilead said a late-stage study of the experimental drug selonsertib aimed at treating NASH failed to meet its main goal. Analysts have projected the market for NASH treatments to reach US$20 billion to US$35 billion as populations increasingly develop the disease fueled by obesity and diabetes.

Without treatment, sufferers can develop advanced damage, including the scarring known as fibrosis; cirrhosis, which destroys liver function; and even cancer.Novo is currently testing semaglutide, already approved to treat diabetes, as a once-daily treatment for NASH in phase 2. Gilead's Cilofexor and firsocostat have not been approved by any regulatory authorities.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

US indicts Indivior over Suboxone opioid treatment marketingREUTERS: The U.S. Justice Department announced on Tuesday the indictment of Indivior Plc and a subsidiary on charges they engaged in an illegal ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Push to cure hepatitis B, a neglected diseaseA coalition of researchers, health organisations and patient groups on Wednesday launched an ambitious campaign to cure hepatitis B, a disease that kills twice as many people as malaria but gets far less attention. 'Inexplicably, despite the huge human and economic toll of chronic hepatitis B (
Source: YahooSG - 🏆 3. / 71 Read more »

Australia 'confident' Assange will receive fair treatment in UKSYDNEY: Australia said it would seek consular access to Queensland-born Julian Assange and expressed confidence he will get legal due process ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

US FDA approves GSK's two-drug HIV treatmentThe U.S. Food and Drug Administration said on Monday it had approved GlaxoSmithKline Plc's two-drug HIV treatment.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

US FDA refuses to review Zogenix's seizure treatmentREUTERS: The U.S. Food and Drug Administration on Monday refused to review the marketing application for Zogenix Inc's treatment for seizures ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »